Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
← catalyst calendarNCT06747858 · readout ≤ 315 d
Sponsored by Arcturus Therapeutics, Inc. (industry) · ARCT — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
33estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-12 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cystic Fibrosis
- CFTR Gene Mutation
Intervention
- Biological: ARCT-032
Primary outcome
what the primary-completion date above is the date OFIncidence, severity and dose relationship of adverse events
measured Cohorts 1-3: 16 weeks and Cohort 4: 24 weeks
Permalink · ARCT's whole pipeline · Catalyst calendar · Every registered study · What changed